INHIBITION OF INFLUENZA VIRUS HAEMAGGLUTINATION: A DIFFERENCE OF BEHAVIOR IN SERA FROM A SINGLE SPECIES.

A. Cohen,S. Newland,Biddlef

DOI: https://doi.org/10.1016/0042-6822(63)90102-8

IF: 3.513

1963-07-01

Virology

Abstract:

What problem does this paper attempt to address?

[Effects of Pirenzepine on Lens-Induced Myopia in the Guinea-Pig].

Chao-hu Ouyang,Ren-yuan Chu,Wen-zheng Hu

DOI: https://doi.org/10.3760/j:issn:0412-4081.2003.06.008

2003-01-01

Abstract:OBJECTIVE:To determine the efficacy of the M(1)-selective muscarinic antagonist, pirenzepine, in preventing lens-induced myopia in the guinea-pig and to study the mechanism and the possibility of treatment of myopia with pirenzepine.METHODS:Fifteen 4-week-old guinea-pigs were monocularly fitted with -10.00 D lenses for a period of 11 days. In Group I (n = 7), both eyes received topical administration of 0.24% saline vehicle as the controls. In Group II (n = 8), the lens-fitted eyes were topically treated with 10% pirenzepine, while the other eyes received the vehicle control. Ocular refraction and biometric measurements were collected on the first and the 11th days. All eyes were finally enucleated for histopathological examination to evaluate the possible toxic effects of pirenzepine.RESULTS:In Group I, 11 days of lens-fitting produced -2.45 D myopia (t = 3.141, P < 0.05) with 0.05 mm elongation of axial dimension (t = 2.500, P < 0.05) as compared to the contralateral eyes. There were no significantly differences of refractive error and axial dimensions between the experimental eyes and the controls in Group II. Histological examinations revealed no obviously toxic effects in the pirenzepine-treated eyes.CONCLUSIONS:Topical administration of the M(1)-selective muscarinic antagonist, pirenzepine, prevents lens-induced experimental myopia in guinea-pig by inhibiting the elongation of axial dimension with no obvious damage to the ocular tissues.
Effect of pirenzepine ophthalmic solution on form-deprivation myopia in the guinea pigs

Qi-hua Le,Neng-neng Cheng,Wei Wu,Ren-yuan Chu

2005-04-05

Abstract:Background: Nonselective muscarinic receptor antagonist, atropine, was believed to inhibit myopic progression. The purpose of this study was to determine the efficacy, through topical administration, of the M1-selective muscarinic antagonist pirenzepine in preventing experimentally induced form-deprivation myopia in guinea pigs. Methods: Fifty-three guinea pigs, which underwent monocular deprivation with their eyelids sutured, were divided into 6 groups. Three groups were treated with 1%, 2% or 4% pirenzepine ophthalmic solutions; the fourth group with atropine; the fifth with saline and the last group left untreated. Ocular refraction, in vivo biometric measurements and wet eye weight were collected before and after the experiment. All the eyes were finally enucleated for histopathological examination to evaluate the possible toxic effects on ocular structures. Results: Animals untreated or treated with saline produced (-2.31+/-1.47) D and (-2.25+/-0.88) D of axial myopia respectively. Those treated with 1% pirenzepine ophthalmic solution produced relative myopia of (-1.63+/-0.48) D, and those under the treatment of 2% and 4% pirenzepine ophthalmic solution only developed a relative myopia of (-0.89+/-0.42) D and (-0.70+/-0.41) D (F=9.56, P<0.05). The significant reduction in myopia in 2% and 4% pirenzepine treated animals was caused by significantly less vitreous chamber elongation and axial elongation of the deprived eyes [2% group: (0.009+/-0.052) mm, 4% group: (0.006+/-0.078) mm] when compared with untreated, saline treated or 1% pirenzepine treated guinea pigs (0.057+/-0.056) mm, (0.064+/-0.053) mm and (0.033+/-0.035) mm, respectively]. Histological examinations revealed no obviously toxic effects on the eyes treated with pirenzepine. Conclusion: Topical administration of the M1-selective muscarinic antagonist, pirenzepine, can prevent induced form-deprivation myopia in guinea pigs by inhibiting axial elongation without obvious damage to ocular tissues.
Study of the pharmacodynamics of pirenzepine iontophoresis for experimental myopia

Yikang DAI,Wei WU,Renyuan CHU

DOI: https://doi.org/10.3760/cma.j.issn.1674-845X.2008.04.017

2008-01-01

Abstract:Objective The purpose of the investigation was to examine the effect of pirenzepine iontophoresis on controlling experimental myopia and the possibility of injury to ocular tissues. Methods Three-week-old guinea pigs were monocularly deprived (MD) by lid-suture for a period of 30 days. During the 30 days, three of the MD groups received daily iontophoresis of pirenzepine (variable current intensity) (PIRx-MD); one group received daily iontophoresis of vehicle (Vehicle 0.3-MD). Control groups (PIR-MD, Atropine-MD, Normal-MD) were used to assess the effects of MD, the iontophoresis regimen, and drug effects. Retinoscopy, anterior/posterior dimensions, and eye weight were measured and a histological examination was performed. Results In Normal-MD and Vehicle 0.3-MD guinea pigs, 30 days of MD produced -4.64 D and -4.33 D of axial myopia, respectively. In pirenzepine iontophoresis MD guinea pigs, 30 days of MD induced an axial myopia of only -2.15 D, -0.17 D and -1.30 D, respectively. The increments in anterior/posterior dimensions were -0.1 mm, 0 mm and -0.1 mm, respectively, in the three PIRx-MD groups, and 0.3 mm in the Normal-MD group. The increments in eye weight were 0 g, 0 g and -0.02 g in the three PIRx-MD groups and 0.02 g in the Normal-MD group. Histological examination revealed no evidence of gross toxic effects. Conclusion Iontophoresis can enhance the corneal penetration of pirenzepine. Chronic administration of pirenzepine by iontophoresis can safely prevent experimentally induced myopia more effectively than topical instillation.
A pharmacodynamic and tolerance study of pirenzepine eye drops in preventing form-deprivation myopia in guinea pigs

LE Qi-hua,CHU Ren-yuan,WU Wei,乐琦骅,褚仁远,吴伟

DOI: https://doi.org/10.3760/cma.j.issn.1674-845X.2006.02.003

2006-01-01

Abstract:Objective To determine the efficacy of an M_1-selective muscarinic antagonist,pirenzepine,in preventing form-deprivation myopia in guinea pigs and to evaluate its tolerance and toxicity.Methods Ten 3-week-old guinea pigs underwent monocular deprivation(MD) for 4 weeks.In the treatment group,MD eyes received a topical administration of 2% pirenzepine.In the control group,MD eyes were topically treated with 0.9% saline.Ocular refraction and biometric measurements were taken.The 2% pirenzepine solution was topically administered to the right eyes of 8 rabbits and a solution of 0.9% saline was administered to the left eyes.Among these,four were treated only once per day while the other four were treated twice a day for 8 consecutive days.Lid,conjunctiva,cornea,iris and lens were observed before and after treatment.All eyes were then enucleated for histopathological examination to evaluate the possible toxic effects of pirenzepine.Results In the control group,MD eyes developed-2.1 D myopia(t=3.5,P<0.05). In the group treated with pirenzepine,MD eyes showed no significant difference in the refractive error or the axial length of the eye.The only exception to these findings occurred one hour after the first treatment with 2% PIR(t=3.46,P<0.05).The findings at other points in time did not differ significantly when compared to the findings before treatment.Histological examination showed no obvious toxic effects in pirenzepine-treated eyes.Conclusion Topical administration of pirenzepine prevents form-deprivation myopia in guinea pigs.It was tolerated well and there were no obvious toxic effects to ocular tissues.
Scleral Cross-Linking Using Riboflavin UVA Irradiation for the Prevention of Myopia Progression in a Guinea Pig Model: Blocked Axial Extension and Altered Scleral Microstructure

Shuai Liu,Shengjie Li,Bingjie Wang,Xiao Lin,Yi Wu,Hong Liu,Xiaomei Qu,Jinhui Dai,Xingtao Zhou,Hao Zhou

DOI: https://doi.org/10.1371/journal.pone.0165792

IF: 3.7

2016-01-01

PLoS ONE

Abstract:PurposeTo develop methods of collagen cross-linking (CXL) in the sclera for the treatment of progressive myopia and to investigate the biomechanical and histological changes that occur in as a result.MethodsTwenty 14-day-old guinea pigs were divided into 3 groups: the cross-linking group (CL, n = 8), non cross-linking group (NCL, n = 8), and control group (n = 4). The scleras of the right eyes of the guinea pigs in the CL group were surgically exposed and riboflavin was dropped onto the irradiation zone for 20 seconds prior to ultraviolet-A (UVA) irradiation. The same procedure was conducted on the NCL group but without UVA irradiation. No procedure was conducted on the control group. The right eyes of the guinea pigs in the CL and NCL groups were then fitted with -10.00DS optics for six weeks. Retinoscopy and the axial lengths (AXL) were measured at baseline, and at the second, fourth and sixth weeks post-treatment in all three groups. All animal subjects were euthanized after the sixth week and then biomechanical and histopathological examinations of the scleras were conducted.ResultsThe mean AXL of the NCL group was longer than both the control and CL groups at six weeks (P = 0.001). The mean refractive error in the NCL group was statistically significantly more negative than both the control and the CL groups at six weeks (P = 0.001). The scleral collagen fiber arrangements of the CL and control groups were denser and more regularly distributed than the NCL group. Ultimate stress of the sclera was lowest in the NCL group, followed by the CL then the control group (P<0.05). Ultimate strain (%) of the sclera was lowest in the CL group followed by the NCL and then the control group (P<0.05).ConclusionOur study demonstrates that scleral CXL using riboflavin UVA irradiation effectively prevents the progression of myopia by increasing scleral biomechanical strength in a guinea pig model.
From edge-disjoint paths to independent paths

Serge Gaspers

2012-03-20

Abstract:Let f(k) denote the maximum such that every simple undirected graph containing two vertices s,t and k edge-disjoint s-t paths, also contains two vertices u,v and f(k) independent u-v paths. Here, a set of paths is independent if none of them contains an interior vertex of another. We prove that f(k)=k if k<3, and f(k)=3 otherwise.
Α-Adrenergic Agonist Brimonidine Control of Experimentally Induced Myopia in Guinea Pigs: A Pilot Study.

Yan Liu,Yuexin Wang,Huibin Lv,Xiaodan Jiang,Mingzhou Zhang,Xuemin Li

2017-01-01

Abstract:Purpose To investigate the efficacy of α-adrenergic agonist brimonidine either alone or combined with pirenzepine for inhibiting progressing myopia in guinea pig lens–myopia-induced models. Methods Thirty-six guinea pigs were randomly divided into six groups: Group A received 2% pirenzepine, Group B received 0.2% brimonidine, Group C received 0.1% brimonidine, Group D received 2% pirenzepine + 0.2% brimonidine, Group E received 2% pirenzepine + 0.1% brimonidine, and Group F received the medium. Myopia was induced in the right eyes of all guinea pigs using polymethyl methacrylate (PMMA) lenses for 3 weeks. Eye drops were administered accordingly. Intraocular pressure was measured every day. Refractive error and axial length measurements were performed once a week. The enucleated eyeballs were removed for hematoxylin and eosin (H&E) and Van Gieson (VG) staining at the end of the study. Results The lens-induced myopia model was established after 3 weeks. Treatment with 0.1% brimonidine alone and 0.2% brimonidine alone was capable of inhibiting progressing myopia, as shown by the better refractive error (p=0.024; p=0.006) and shorter axial length (p=0.005; p=0.0017). Treatment with 0.1% brimonidine and 0.2% brimonidine combined with 2% pirenzepine was also effective in suppressing progressing refractive error (p=0.016; p=0.0006) and axial length (p=0.017; p=0.0004). The thickness of the sclera was kept stable in all groups except group F; the sclera was much thinner in the lens-induced myopia eyes compared to the control eyes. Conclusions Treatment with 0.1% brimonidine alone and 0.2% brimonidine alone, as well as combined with 2% pirenzepine, was effective in inhibiting progressing myopia. The result indicates that intraocular pressure elevation is possibly a promising mechanism and potential treatment for progressing myopia.
Increased Choroidal Blood Perfusion Can Inhibit Form Deprivation Myopia in Guinea Pigs

Xuan Zhou,Sen Zhang,Guoyun Zhang,Yizhong Chen,Yi Lei,Jing Xiang,Renchang Xu,Jia Qu,Xiangtian Zhou

DOI: https://doi.org/10.1167/iovs.61.13.25

2020-11-02

Abstract:Purpose: In guinea pigs, choroidal thickness (ChT) and choroidal blood perfusion (ChBP) simultaneously decrease in experimental myopia, and both increase during recovery. However, the causal relationship between ChBP and myopia requires further investigation. In this study, we examined the changes of ChBP with three different antimyopia treatments. We also actively increased ChBP to examine the direct effect on myopia development in guinea pigs. Methods: Experiment 1: Guinea pigs wore occluders on the right eye for two weeks to induce form-deprivation myopia (FDM). Simultaneously they received daily antimyopia treatments: peribulbar injections of atropine or apomorphine or exposure to intense light. Experiment 2: The vasodilator prazosin was injected daily into the form-deprivation eyes to increase ChBP during the two-week induction of FDM. Other FDM animals received appropriate control treatments. Changes in refraction, axial length, ChBP, ChT, and hypoxia-labeled pimonidazole adducts in the sclera were measured. Results: The antimyopia treatments atropine, apomorphine, and intense light all significantly inhibited myopia development and the decrease in ChBP. The treatments also reduced scleral hypoxia, as indicated by the decrease in hypoxic signals. Furthermore, actively increasing ChBP with prazosin inhibited the progression of myopia, as well as the increase in axial length and scleral hypoxia. Conclusions: Our data strongly indicate that increased ChBP attenuates scleral hypoxia, and thereby inhibits the development of myopia. Thus ChBP may be a promising target for myopia retardation. As such, it can serve as an immediate predictor of myopia development as well as a long-term marker of it.
Inhibition of matrix metalloproteinase activity in the chick sclera and its effect on myopia development

Hsin-Hua Liu,Alex Gentle,Andrew I Jobling,Neville A McBrien

DOI: https://doi.org/10.1167/iovs.09-4322

Abstract:Purpose: To investigate the contribution of matrix degradation in the two-layer avian sclera to the development of myopia. Methods: Tissue inhibitor of metalloproteinase-2 (TIMP-2) was used to inhibit chick scleral collagen degradation with (3)H-proline, a marker for this effect. Ex vivo scleral culture experiments confirmed TIMP-2 doses for in vivo experimentation. Ocular growth and refractive response to exogenous TIMP-2 (11.25, 2.25, and 0.45 picomoles, plus vehicle only) were monitored in 7-day-old chicks during the induction of myopia over 4 days with a translucent occluder. Collagen degradation was assessed, in whole sclera and in separated scleral layers by using the same paradigm (11.25 picomoles TIMP-2; vehicle only). Results: Approximately 60% of collagen degradation was inhibited with low (2 nM) doses of TIMP-2 in the ex vivo sclera. Degradative activity in the in vivo chick sclera increased significantly (46%) during myopia development, with all the altered activity confined to the fibrous layer. Addition of TIMP-2 significantly reduced (by 46%) this accelerated scleral collagen degradation, also by acting in the fibrous layer. TIMP-2 had no significant effect on (3)H-proline incorporated in the cartilaginous scleral layer and cornea. Despite inhibiting collagen degradation TIMP-2 had no significant effect on myopia development. Conclusions: Increased collagen degradation is a feature of scleral remodeling in chick myopia development, but is confined to the fibrous scleral layer. Significant inhibition of this collagenolytic activity with TIMP-2 has little effect on refractive error development, suggesting that collagen degradation in the sclera contributes little to the development of myopia in the chick.
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.

P. Jacobsen,A. Mahableshwarkar,Yinzhong Chen,L. Chrones,A. Clayton

DOI: https://doi.org/10.1111/jsm.12980

2015-10-01

Abstract:INTRODUCTION Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), and does not resolve in most patients. Vortioxetine, an antidepressant with a multimodal mechanism of action, has shown low rates of sexual dysfunction in previous major depressive disorder (MDD) trials. AIM This study compared the effects of vortioxetine and escitalopram on sexual functioning in adults with well-treated MDD experiencing treatment-emergent sexual dysfunction (TESD). METHODS Participants treated with, and responding to, citalopram, paroxetine, or sertraline were randomized to switch to either vortioxetine (10/20 mg; n = 225) or escitalopram (10/20 mg; n = 222) for 8 weeks. Sexual function was assessed using the Changes in Sexual Functioning Questionnaire Short Form (CSFQ-14), and antidepressant efficacy was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impressions (CGI) scale, and Profile of Mood States brief form (POMS-brief). Safety and tolerability were also assessed. MAIN OUTCOME MEASURES The primary endpoint was change from baseline in the CSFQ-14 total score after 8 weeks of treatment. The MADRS, CGI, and POMS-brief were used to assess antidepressant efficacy. Safety was assessed via adverse events, vital signs, electrocardiograms, laboratory values, weight, and physical examination findings. RESULTS Vortioxetine showed significantly greater improvements in CSFQ-14 total score (8.8 ± 0.64, mean ± standard error) vs. escitalopram (6.6 ± 0.64; P = 0.013). Benefits vs. escitalopram were significant on four of five dimensions and all three phases of sexual functioning assessed by the CSFQ-14 (P < 0.05). Antidepressant efficacy continued in both groups, with similar, but slight, improvements in MADRS and CGI scores. Vortioxetine and escitalopram had similar clinical efficacy profiles in this study, with safety profiles similar to previous trials. Nausea (n = 9, 4.0%) was the most common treatment-emergent adverse event leading to discontinuation of vortioxetine. CONCLUSION Switching antidepressant therapy to vortioxetine may be beneficial for patients experiencing sexual dysfunction during antidepressant therapy with SSRIs.
Effects of muscarinic agents on chick choroids in intact eyes and eyecups: evidence for a muscarinic mechanism in choroidal thinning

Debora L Nickla,Xiaoying Zhu,Josh Wallman

DOI: https://doi.org/10.1111/opo.12054

Abstract:Purpose: In chicks, ocular growth inhibition is associated with choroidal thickening and growth stimulation with choroidal thinning, suggesting a mechanistic link between the two responses. Because muscarinic antagonists inhibit the development of myopia in animal models by a non-accommodative mechanism, we tested the hypothesis that agonists would stimulate eye growth and thin the choroid. We also hypothesized that the effective growth-inhibiting antagonists would thicken the choroid. Methods: Chicks, age 12-16 days, were used. In vivo: Agonists: Single intravitreal injections (20 μL) of oxotremorine (oxo), pilocarpine (pilo), carbachol (carb), or arecaidine (arec) were given to otherwise untreated eyes. A-scan ultrasonography was done prior to injections, and at 3, 24, 48 and 72 h. Antagonists: -10D lenses were worn on one eye for 4 days. Atropine (atro), pirenzepine (pirz), oxyphenonium (oxy) or dicyclomine (dicy) were injected (20 μL) daily into lens-wearing eyes; saline injections were done as controls. Ultrasonography was done on d1 and on d4; on d4 measurements were done before and 3 h after injections. In vitro: Paired eyecups of retinal pigment epithelium (RPE), choroid and sclera were made from 1-week old chicks. All drugs except atropine were tested on one eyecup, its pair in plain medium. Choroidal thickness was measured at various times over 48 h. Results: Agonists: In vivo, oxotremorine caused an increase in the rate of axial elongation (drug vs saline: 24-72 h: 338 μm vs 250 μm; p < 0.001). All except pilocarpine caused choroidal thinning by 24 h (oxo, carb and arec vs saline: -25, -35 and -46 μm vs 3 μm). In vitro, all agonists thinned choroids by 24 h (oxo: -6 vs 111 μm; pilo: 45 vs 212 μm; carb: -58 vs 65 μm; arec: 47 vs 139 μm; p < 0.05). Antagonists: Atropine, pirenzepine and oxyphenonium inhibited the development of myopia in negative lens-wearing eyes, and also caused choroidal thickening (drug vs saline: 42, 80, 88 vs 10 μm per 3 h). In vitro, pirenzepine thickened choroids by 3 h (77 vs 2 μm, p < 0.01). Conclusions: Muscarinic agonists caused choroidal thinning in intact eyes and eyecups, supporting a role for acetylcholine in the choroidal response to hyperopic defocus or form deprivation. Only oxotremorine stimulated eye growth, which is inconsistent with a muscarinic receptor mechanism for antagonist-induced eye growth inhibition. The dissociation between choroidal thinning and ocular growth stimulation for the other agonists in vivo suggest separate pathways for the two.
Decreased Choroidal Blood Perfusion Induces Myopia in Guinea Pigs

Xuan Zhou,Sen Zhang,Fan Yang,Yaozhen Yang,Qin Huang,Chengjie Huang,Jia Qu,Xiangtian Zhou

DOI: https://doi.org/10.1167/iovs.62.15.30

2021-01-01

Abstract:PURPOSE. The development of myopia in guinea pigs can be inhibited by attenuating scleral hypoxia by increasing choroidal blood perfusion (ChBP). In this study, we reduced ChBP through surgical and pharmacological methods to determine the effect on myopia development. We also determined whether ChBP was reduced by quinpirole, a drug that enhances form-deprivation myopia (FDM). METHODS. ChBP was reduced in the right eyes of guinea pigs via transection of the temporal ciliary arteries or daily injections of phenylephrine into the inferior peribulbar space for one week during normal ocular growth. Other guinea pigs were subjected to two weeks of monocular FDM-with facemasks, along with daily injections of quinpirole, a dopamine D2 receptor agonist, to enhance the FDM. Changes in refraction, axial length, ChBP, and choroidal thickness (ChT) were measured in both treated and fellow eyes of the treatment and control groups. Scleral hypoxia labeling with pimonidazole adducts and alpha-smooth muscle actin (alpha-SMA) protein were also measured. RESULTS. Surgical and pharmacological reduction of ChBP induced myopia development in the treated eyes. These treatments rendered the scleral hypoxia and increased scleral alpha-SMA expression. Furthermore, quinpirole injections, which increased the magnitude of myopia, augmented the FDM-associated reductions in ChBP and ChT and increased the levels of scleral hypoxia and alpha-SMA protein. CONCLUSIONS. Decreased ChBP in guinea pigs leads to scleral hypoxia and scleral myofibroblast transdifferentiation with increased alpha-SMA expression, ultimately resulting in myopia development. In future clinical trials, ChBP reduction can serve as a potential biomarker for early detection of myopia development.
Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes

G J Lind,S J Chew,D Marzani,J Wallman

Abstract:Purpose: Muscarinic acetylcholine receptors (mAChRs) have been implicated in the control of myopia in humans and in animal models. This study was conducted to determine whether mAChRs influence the growth of the chick sclera and, if so, which mAChR subtypes are involved. Methods: Sclera and scleral chondrocytes from normal and form-deprived eyes of 10- to 14-day-old chicks were treated with a total of seven ligands: two agonists, carbachol (nonselective) and McN-A-343 (selective for the M1 mAChR subtype); and five antagonists, atropine (nonselective), pirenzepine and telenzepine (M1), gallamine (M2), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; M1 and M3). Incorporation of sulfate into glycosaminoglycans and of thymidine into DNA were quantified and normalized to sample DNA content. Possible toxicity of ligands at high doses was examined by analysis of cell number (by cell counting), viability (by trypan blue exclusion), and cellular metabolic activity (by dehydrogenase activity). Results: Cellular proliferation and extracellular matrix production were inhibited by atropine in whole sclera and in its cartilaginous layer. Sulfate incorporation by chondrocytes from normal and form-deprived eyes was inhibited by mAChR antagonists with a rank order of potency (atropine > pirenzepine = 4-DAMP >> gallamine) consistent with regulation by M1, rather than M3 or M2 mAChR subtypes. Pirenzepine inhibited sulfate incorporation by chondrocytes from form-deprived eyes more effectively than those from normal eyes. Chondrocyte cultures were not viable when grown in high doses of any of the ligands used except gallamine. Conclusions: In chick scleral chondrocytes, synthesis of DNA and glycosaminoglycans was inhibited by mAChR antagonists. This inhibition was probably mediated by the M1 subtype mAChR. Therefore in vivo the sclera may be a site of action for the mAChR antagonists previously used to influence myopia. Although at high concentrations mAChR antagonists tested seemed to be toxic to chondrocytes, at lower doses inhibition occurred without toxic effects.
Effects of intravitreally and intraperitoneally injected atropine on two types of experimental myopia in chicken

Sigrid Diether,Frank Schaeffel,George N Lambrou,Christine Fritsch,Anne-Ulrike Trendelenburg

DOI: https://doi.org/10.1016/j.exer.2006.09.019

Abstract:Atropine, a non-selective muscarinic receptor antagonist, is currently the most potent agent used to prevent myopia in animal models and children. However, the ocular target tissues are not well defined. To learn more about the effect of atropine on experimental myopia, atropine was applied both intravitreally and systemically (intraperitoneally) to chickens wearing either negative lenses or light diffusers. Furthermore, the effect of ipsilateral intravitreal atropine on myopia development in the saline-treated fellow eye was studied. Monocular intravitreal injections of atropine were performed daily for a period of 4 successive days, starting at day 8 post-hatching. Fellow eyes received saline injections. Chicks were fitted with -7D lenses, either over the atropine-injected eyes only (unilateral "lens-induced myopia (LIM)"), or over both eyes (bilateral LIM). Other groups of chicks were fitted with translucent diffusers over the atropine-injected eyes (unilateral "form deprivation myopia (FDM)"). Finally, atropine was intraperitoneally injected for 4 days in chicks that wore monocularly -7D lenses. Refractive errors (RE) were measured with infrared photoretinoscopy and axial length (AL) with A-scan ultrasonography. Atropine prevented development of myopia in both unilateral LIM and FDM in a dose-dependent fashion. Fifty percent inhibition of myopia was observed at a dose of 25 microg (unilateral LIM) or 90 microg atropine (bilateral LIM) and complete inhibition at 750 microg; in unilateral FDM, 50% inhibition occurred at 2.5 microg and almost 100% inhibition at 250 microg. Interestingly, at the highest dose of atropine (2500 microg), the treated eyes became even more hyperopic compared to the saline-injected contralateral eyes with normal visual experience. In the bilateral LIM model, atropine suppressed development of myopia in both the treated and the saline-injected control eye. However, about 8.3 times higher doses were necessary to achieve comparable contralateral suppression. Since this ratio is lower than the vitreous volume to blood volume ratio (about 1:23 in young chicks), it seems unlikely that systemic dilution of the intravitreally injected drug can fully account for the contralateral suppression. Intraperitoneal injection inhibited myopia development only at the highest dose (2500 microg) but, strikingly, this inhibition was still less when the same dose was provided through the vitreous of the fellow eye. Both eyes seem to be coupled by a yet unknown, perhaps neuronal pathway. Estimations of the scleral concentrations of atropine after intravitreal injection are compatible with the assumption that the suppression of myopia by atropine occurs by direct inhibition of scleral chondrocytes.
Streptokinase still lysing coronary clots.

P. Gunby

DOI: https://doi.org/10.1001/JAMA.1983.03340200004002

1983-11-25

Abstract:While tissue-type plasminogen activator (t-PA) is the big news in thrombolytic therapy for an evolving myocardial infarction (MI), evaluation of streptokinase for the same purpose is continuing news ( JAMA 1981;245:689-694, 1982;248:805-811). In recent weeks, discussions at meetings sponsored by the Texas Heart Institute in Houston, the American College of Chest Physicians in Chicago, and the American Heart Association in Anaheim, Calif, have addressed these questions: How do results of streptokinase thrombolysis compare with results of other attempts to halt or limit an evolving MI? Should streptokinase be administered via an intracoronary or peripheral intravenous (IV) route? How soon should streptokinase be administered, and for how long, and what are the benefits in terms of survival and heart function? Part of the answer to the first question may come from an ongoing prospective study supported by the National Heart, Lung, and Blood Institute (NHLBI), Bethesda, Md. The study
Modulation of scleral DNA synthesis in development of and recovery from induced axial myopia in the tree shrew

A Gentle,N A McBrien

DOI: https://doi.org/10.1006/exer.1998.0587

Abstract:Visually modulated scleral extracellular matrix remodelling is associated with the development of, and recovery from, induced axial myopia in the tree shrew, a commonly used mammalian model of refractive error development. The involvement of scleral cell proliferation in this process was investigated using [3H] thymidine. Tree shrews were monocularly deprived of pattern vision, using translucent occluders, or the retinal image was optically defocused, using negative lenses, over a period of 5 days. A further group was monocularly deprived for 5 days, then allowed 3 days of binocular recovery. A control group of binocularly open animals was employed to establish normal parameters. On the final day of the experimental period, [3H] thymidine was administered by intraperitoneal injection, then optical and biometric measures were taken and tissue samples collected for assay. Incorporation of [3H] thymidine into cellular DNA was measured in proteinase K digests, following precipitation with trichloroacetic acid. After 5 days, significant amounts of myopia were present in the treated eyes of both form-deprived [-7. 0+/-0.7 Dioptres (D), group mean+/-s.e.m.; P<0.01] and lens-defocused animals (-6.2+/-0.9 D;P<0.01). After 3 days of recovery, 50% of the refractive error had been compensated for, predominantly through shortening of the vitreous chamber in the treated eye. Reduced levels of [3H] thymidine incorporation were observed in sclera from both groups of myopic animals (form-deprived, -34.3+/-9.9%;P<0.05 and lens-defocus, -32.8+/-4.5%;P<0.005). Increased levels of [3H] thymidine incorporation were found in the sclera of recovering animals (+144.0+/-43.2%;P<0.05). The results show that changes in regulation of cell proliferation, during the development of myopia, are visually mediated and inversely related to the direction of change in ocular size. This implies that alterations in the scleral fibroblast population are involved in the modulation of scleral matrix turnover during myopia development.
Diisopropylfluorophosphate alters retinal neurotransmitter levels and reduces experimentally-induced myopia

C L Cottriall,J Brew,K A Vessey,N A McBrien

DOI: https://doi.org/10.1007/s002100100460

Abstract:The excessive enlargement of the eye seen in myopia is known to be regulated, in part, by retinal neurotransmitters. One excitatory retinal neurotransmitter, acetylcholine, has been implicated in the signal cascade through the effectiveness of the muscarinic antagonist, atropine, in preventing myopia development. The present study therefore examined whether an indirect cholinomimetic, diisopropylfluorophosphate (DFP), could increase the level of experimental myopia, induced by the deprivation of pattern vision. Injections of either phosphate-buffered DFP or phosphate-buffered saline were made every 48 h into the vitreous chamber of one eye of chicks. The injected eye was then deprived of pattern vision by a translucent occluder. The fellow eye remained untreated and acted as a genetic control. At the end of the treatment period (8 days) axial ocular dimensions and cycloplegic refractive error were measured. To investigate the effects of DFP on retinal neurotransmitter levels, measurements of acetylcholine and dopamine contents were made on retinal tissue following either a single or multiple DFP injections, using reverse phase high performance liquid chromatography (HPLC). Rather than potentiating myopia and vitreous chamber elongation, a significant reduction in myopia (58%) was observed in DFP-injected deprived eyes, compared to saline controls. However, open eyes injected with DFP showed no difference in refraction or vitreous chamber depth compared to contralateral control eyes or saline controls. HPLC analysis revealed increased steady-state content of acetylcholine (+34 +/- 6 ng/mg protein, mean +/- SEM, P<0.01, equivalent to a 54% increase) and dopamine (+377 +/- 83 pg/mg protein, P<0.01, a 36% increase) in DFP-treated eyes compared to contralateral control eyes following a single DFP injection. No changes in either acetylcholine or dopamine content were found in saline-treated control animals. Injection of dopamine antagonists, in combination with DFP, indicated that the DFP-induced reduction in myopia is mediated, at least in part, through a D2 receptor mechanism. Findings argue against a direct cholinergic 'stop-go' pathway controlling ocular growth. Instead the reduction of induced myopia could be related to the action of DFP (directly or indirectly) on dopamine levels in the retina.
Clinical analysis in intact erythrocytes using 1H spin echo NMR.

J. Reglinski,W. Smith,Rhoda Wilson,L. Buchanan,J. H. McKillop,J. Thomson,M. Brzeski,M. Brzeski,M. Marabani,M. Marabani,R. D. Sturrock,R. D. Sturrock

DOI: https://doi.org/10.1016/0009-8981(91)90023-6

1991-09-14

Abstract:
[Considerations on the use of ampicillin in dermo-venereal patients].

C. Lazzaro

1965-09-12

Minerva Medica

Abstract:
Crosstalk Between Ep2 And Ppar Alpha Modulates Hypoxic Signaling And Myopia Development In Guinea Pigs

Nethrajeith Srinivasalu,Sen Zhang,Renchang Xu,Peter Sol Reinach,Yongchao Su,Yun Zhu,Jia Qu,Xiangtian Zhou

DOI: https://doi.org/10.1167/iovs.61.8.44

2020-01-01

Abstract:PURPOSE. Cyclic adenosine monophosphate (cAMP) and peroxisome proliferator-activated receptor alpha (PPAR alpha) levels mediate extracellular matrix (ECM) changes by altering the levels of hypoxia-inducible factor 1-alpha (HIF-1 alpha) in various tissues. We aimed to determine, in the sclera of guinea pigs, whether a prostanoid receptor (EP2)-linked cAMP modulation affects PPAR alpha and HIF-1 alpha signaling during myopia.METHODS. Three-week-old guinea pigs (n = 20 in each group), were monocularly injected with either an EP2 agonist (butaprost 1 mu mol/L/10 mu mol/L), an antagonist (AH6809 10 mu mol/L/30 mu mol/L) or a vehicle solution for two weeks during normal ocular growth. Separate sets of animals received these injections and underwent form deprivation (FD) simultaneously. Refraction and axial length (AL) were measured at two weeks, followed by scleral tissue isolation for quantitative PCR (qPCR) analysis (n = 10) and cAMP detection (n = 10) using a radioimmunoassay.RESULTS. Butaprost induced myopia development during normal ocular growth, with proportional increases in AL and cAMP levels. FD did not augment the magnitude of myopia or cAMP elevations in these agonist-injected eyes. AH6809 suppressed cAMP increases and myopia progression during FD, but had no effect in a normal visual environment. Of the diverse set of 27 genes related to cAMP, PPAR alpha and HIF-1 alpha signaling and ECM remodeling, butaprost differentially regulated 15 of them during myopia development. AH6809 injections during FD negated such differential gene expressions.CONCLUSIONS. EP2 agonism increased cAMP and HIF-1 alpha signaling subsequent to declines in PPARa and RXR mRNA levels, which in turn decreased scleral fibrosis and promoted myopia. EP2 antagonism instead inhibited each of these responses. Our data suggest that EP2 suppression may sustain scleral ECM structure and inhibit myopia development.

INHIBITION OF INFLUENZA VIRUS HAEMAGGLUTINATION: A DIFFERENCE OF BEHAVIOR IN SERA FROM A SINGLE SPECIES.

[Effects of Pirenzepine on Lens-Induced Myopia in the Guinea-Pig].

Effect of pirenzepine ophthalmic solution on form-deprivation myopia in the guinea pigs

Study of the pharmacodynamics of pirenzepine iontophoresis for experimental myopia

A pharmacodynamic and tolerance study of pirenzepine eye drops in preventing form-deprivation myopia in guinea pigs

Scleral Cross-Linking Using Riboflavin UVA Irradiation for the Prevention of Myopia Progression in a Guinea Pig Model: Blocked Axial Extension and Altered Scleral Microstructure

From edge-disjoint paths to independent paths

Α-Adrenergic Agonist Brimonidine Control of Experimentally Induced Myopia in Guinea Pigs: A Pilot Study.

Increased Choroidal Blood Perfusion Can Inhibit Form Deprivation Myopia in Guinea Pigs

Inhibition of matrix metalloproteinase activity in the chick sclera and its effect on myopia development

Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.

Effects of muscarinic agents on chick choroids in intact eyes and eyecups: evidence for a muscarinic mechanism in choroidal thinning

Decreased Choroidal Blood Perfusion Induces Myopia in Guinea Pigs

Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes

Effects of intravitreally and intraperitoneally injected atropine on two types of experimental myopia in chicken

Streptokinase still lysing coronary clots.

Modulation of scleral DNA synthesis in development of and recovery from induced axial myopia in the tree shrew

Diisopropylfluorophosphate alters retinal neurotransmitter levels and reduces experimentally-induced myopia

Clinical analysis in intact erythrocytes using 1H spin echo NMR.

[Considerations on the use of ampicillin in dermo-venereal patients].

Crosstalk Between Ep2 And Ppar Alpha Modulates Hypoxic Signaling And Myopia Development In Guinea Pigs